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Abstract
Introduction: The microenvironment surrounding inflamed synovium leads to the activation of fibroblast-like
synoviocytes (FLSs), which are important contributors to cartilage destruction in rheumatoid arthritic (RA) joints.
Transglutaminase 2 (TG2), an enzyme involved in extracellular matrix (ECM) cross-linking and remodeling, is
activated by inflammatory signals. This study was undertaken to assess the potential contribution of TG2 to FLS-
induced cartilage degradation.
Methods: Transglutaminase (TGase) activity and collagen degradation were assessed with the
immunohistochemistry of control, collagen-induced arthritic (CIA) or TG2 knockdown (shRNA)-treated joint tissues.
TGase activity in control (C-FLS) and arthritic (A-FLS) rat FLSs was measured by in situ 5-(biotinamido)-pentylamine
incorporation. Invadopodia formation and functions were measured in rat FLSs and cells from normal (control; C-
FLS) and RA patients (RA-FLS) by in situ ECM degradation. Immunoblotting, enzyme-linked immunosorbent assay
(ELISA), and p3TP-Lux reporter assays were used to assess transforming growth factor-b (TGF-b) production and
activation.
Results: TG2 and TGase activity were associated with cartilage degradation in CIA joints. In contrast, TGase activity
and cartilage degradation were reduced in joints by TG2 knockdown. A-FLSs displayed higher TGase activity and
TG2 expression in ECM than did C-FLSs. TG2 knockdown or TGase inhibition resulted in reduced invadopodia
formation in rat and human arthritic FLSs. In contrast, increased invadopodia formation was noted in response to
TGase activity induced by TGF-b, dithiothreitol (DTT), or TG2 overexpression. TG2-induced increases in invadopodia
formation were blocked by TGF-b neutralization or inhibition of TGF-bR1.
Conclusions: TG2, through its TGase activity, is required for ECM degradation in arthritic FLS and CIA joints. Our
findings provide a potential target to prevent cartilage degradation in RA.
Introduction
Rheumatoid arthritis is a disabling autoimmune disease
characterized by a chronic state of inflammation that
can affect several organs and tissues, although small
joints of patients are most commonly affected. The
increased inflammatory cell infiltration of the synovium
is accompanied by a modification of the resident syno-
vial cell population. Activation of fibroblast-like synovio-
cytes (FLSs) leads to the release of a broad array of
mediators that act on cells of the immune system as
well as resident joint cells, exacerbating the inflamma-
tory response and resulting in articular cartilage and
bone damage [1].
Many factors present in the inflamed microenvironment
of the joints have been shown to activate FLSs. These
include various cytokines and chemokines [2-4], growth
factors [5], extracellular matrix fragments [6,7], and
hypoxia [8]. The selective pressure from the inflammatory
environment generates intrinsic changes in RA-FLSs lead-
ing to an enhanced ability to attach to cartilage, invade
through matrix, and synthesize degradative enzymes [9].
We recently reported that the ability of A-FLSs to degrade
ECM is dependent on the formation of specialized struc-
tures resembling invadopodia in tumor cells, which are
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invasive structures involved in basement membrane degra-
dation, or podosomes, the bone-resorbing structures
found in osteoclasts [10,11]. Characterization of the A-FLS
structures indicated that they contained actin components,
activated kinases (Scr), and the metalloproteinases MMP3
and MMP-13, which are known to be particularly efficient
at inducing cartilage degradation. They were found in cells
at the cartilage/pannus junction, well positioned for carti-
lage degradation. Importantly, interference with the for-
mation of invadopodia in A-FLSs by Src kinase inhibition
impeded ECM degradation in vitro and cartilage degrada-
tion in a model of collagen-induced arthritis (CIA) [11],
strongly suggesting that invadopodia are physiological
structures involved in cartilage destruction.
Transglutaminase 2 (TG2) is a multifunctional enzyme
that has been associated with wound healing and inflam-
matory diseases (for review, see [12]). TG2 is ubiquitous
and generally located in the cytosol in a catalytically inac-
tive form because of low intracellular calcium and high
GTP concentrations. It can also be found in the nucleus,
the inner surface of the plasma membrane, or can be
secreted, in which case, it localizes in the ECM or at the
cell surface [13]. TG2 is known mostly for its ability to
catalyze the cross-linking of proteins by transamidation
of a glutamine residue to a lysine residue, a reaction that
requires Ca2+ [14]. The resulting ε-(g-glutamyl)-lysine
bond is resistant to proteases and confers increased stabi-
lity to protein complexes involved in cellular functions,
including apoptosis and matrix remodeling. Besides its
transglutaminase (TGase) activity, TG2 can act as a pro-
tein disulfide isomerase and can display protein kinase,
GTPase, and DNA nuclease activities [15-17]. TG2 can
also serve as an adaptor to facilitate cell adhesion to
fibronectin by interacting with b-integrins, syndecan, or
cell-adhesion receptors [18-20]. The expression of TG2 is
regulated by cytokines and growth factors involved in
inflammation, and TG2 was found to be overexpressed in
the RA synovium [12]. Transforming growth factor-b
(TGF-b) induces TG2 expression through its effect on a
response element located in the promoter region of the
gene [21]. TG2, in turn, can upregulate the expression of
TGF-b through nuclear factor (NF)-B activation, which
is concomitant with an increase in bioactive TGF-b in
the extracellular environment [22], thus enforcing a posi-
tive-feedback loop. TG2 expression is also increased by
TNF-a through NF-B activation in liver cells [23] and
by interleukin-1 (IL-1) in cartilage tissues [24]. TG2 over-
expression is linked to increased aggressivity in many
cancer cells [25], whereas TG2-knockout mice show
reduced cartilage degradation in a model of osteoarthritis
[26].
TG2 and the degradation capacity of activated FLSs are
both stimulated as the result of the inflammatory envir-
onment present in the arthritic synovium. We therefore
investigated the impact of the modulation of TG2 levels
and/or activity on cartilage degradation in CIA rats and
in invadopodia formation in FLSs. We showed that the
TGase activity of TG2 was associated with collagen type
II degradation in CIA joints. Of significance, knockdown
of TG2 resulted in a strong reduction in the degradation
of collagen. We further demonstrated, for the first time,
that the regulation of invadopodia formation was related
to the TGase activity of TG2, and that this effect
was dependent on TGF-b signaling. Taken together, our
findings provide evidence of the existence of a new TG2-
dependent pathway that influences FLS-mediated degra-
dation in arthritic joints.
Materials and methods
Induction and clinical evaluation of arthritis
All experimental procedures involving animals were
conducted under protocols approved by the Ethics
Committee on Animal Research of the University of
Sherbrooke, in accordance with regulations of the Cana-
dian Council on Animal Care. Female Lewis/SsNHsd
rats (100 to 124 g) were purchased from Charles River
Laboratories (St-Constant, QC, Canada). Arthritis was
induced by intradermal injection of type II collagen at
the base of the tail, as described [11]. In the case of
in vivo TG2 inhibition, rats received one intraarticular
injection of 3 × 109 units of a lentivirus harboring TG2-
shRNA or control (scrambled) shRNA, 10 days after
CIA induction.
Histology
Tissue sections from the left hind-knee joints were pro-
cessed immediately after excision by following a standar-
dized paraffin-embedding protocol. Tissue sections were
rehydrated, treated with trypsin 1%, and immunohisto-
chemical staining was performed according to the stan-
dard avidin-biotin immunoperoxidase complex technique
by using a mouse monoclonal ε-(g-glutamyl)-lysine bond
antibody (Abcam (Cambridge, MA, USA) ab424; 1:100), a
rabbit polyclonal collagenase cleaved type I and II collagen
(Col 2 3/4 short) antibody (Ibex Pharmaceutical (Mon-
treal, QC, Canada) Ab 50-1035; 1:75), or a mouse mono-
clonal TG2 (Thermo Scientific (Rockford, IL, USA)
TG100; 1:50). DAB, SG, or VIP (Vector Laboratories Inc.,
Burlington, ON, Canada) was used for the detection of
labeled proteins. Some sections were counterstained with
Harris hematoxylin. Tissue sections from rats in each
group were treated simultaneously to palliate interexperi-
mental staining variations.
Modified Mankin grading
Sections were stained by using hematoxylin/eosin and
the safranin O/Fast green staining protocols to allow
visualization of cartilage structure. Pathology scores
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were evaluated for each tissue section by three blinded
observers using a modified Mankin scoring system, as
described [27]. In the cartilage structure subcategory of
the scoring system, the extent of cartilage invasive zones
was evaluated instead of cartilage clefts, the better to
account for the cartilage changes observed in CIA.
Analysis of immunolabeled specimens
Analysis of joint section (synovial membrane and carti-
lage) was performed by using an Axioskop 2 phase-con-
trast/epifluorescence microscope (Carl Zeiss, Inc.,
Toronto, ON, Canada) equipped with a 10× or 40×
objective at the same level of incident illumination for
each slide in the experiment. The condenser was adjusted
to bright-field transmission light microscopy. Photomi-
crographs of six (for 40× magnification) or three (for 10×
magnification) random areas within the synovial mem-
brane or cartilage were captured with Retiga SRV cooled
color digital camera (Qimaging, Surrey, BC, Canada).
The intensity of labeling in the synovial membrane or a
representative portion of cartilage in each image was ana-
lyzed by using the IHC quantification technique validated
by Pham et al. [28]. Images were converted to CMYK in
the FIJI software (Open Source). Next, the gray image of
the yellow (Y) channel was extracted, and chromogen
intensities were analyzed by using the Image Pro software
(Media Cybernetics Inc., Bethesda, MD, USA). Results
are expressed as the sum of labeling intensity (density)
relative to the total area, from two different tissue
sections for each rat.
Cell cultures
Synovial membranes were removed from the right hind-
knee joints of experimental rats, and cells were isolated
by collagenase type IV digestion, as described [29]. Four
human cell lines isolated from patients diagnosed with
RA and undergoing arthroplasty (RA-FLS) or three cell
lines isolated from control joints with no evidence of dis-
ease (C-FLS) were obtained from Asterand (Detroit, MI,
USA). All synovial tissues were obtained with Institu-
tional Review Board approval and appropriate informed
consent. Cells were cultured in DMEM-F12 supplemen-
ted with 10% FBS and 40 μg/ml gentamycin. The cells
were used between passages 3 and 8.
Plasmids and transfections
pcDNA3.1-wtTG2 and pcDNA3.1-W241A-TG2 were gen-
erously provided by Dr. Gail V.W. Johnson (University of
Rochester, Rochester, NY, USA). GFP-lentiviral shRNAs
targeting rat TG2 and control (scrambled) shRNA plas-
mids were from ezBiolab (Carmel, IN, USA). Control and
mouse/rat FXIIIA targeting pLKO.1-shRNA plasmids
were from Thermo Scientific. Viral particles were gener-
ated by transient transfection of 293T cells with the
ViraPower lentiviral expression system (Invitrogen, Bur-
lington, ON, Canada). Synoviocytes were tested in the dif-
ferent assays 24 hours after transient transfection by using
Fugene 6 (Roche Diagnostics, Laval, QC, Canada) or
48 hours after lentivirus infection with Polybrene (5 μg/ml;
Santa Cruz Biotechnology, Santa Cruz, CA, USA). With
this procedure, a high efficiency (about 60%) of lentivirus
infection was achieved in both rat and human synoviocytes.
Cells expressing FXIIIa-shRNAs were selected with a
72-hour puromycin treatment.
Invadopodia assays
Coverslips were prepared by using Oregon Green488-con-
jugated gelatin (Invitrogen) at a final concentration of
1%, as described [30]. Thirty thousand cells were seeded
on each coverslip and incubated for 40 hours. Cells were
fixed with 1% paraformaldehyde and stained with DAPI
and Alexa647-conjugated phalloidin (Invitrogen). Cells
were visualized with fluorescence microscopy. Invadopo-
dia were identified by actin-rich areas of matrix degrada-
tion characterized by loss of green fluorescence. Three
hundred cells were counted per coverslip. In the case of
TG2-overexpressing cells, TG2 was labeled by using anti-
TG2 antibodies (Thermo Scientific CUB7402), and inva-
dopodia formation was counted for TG2-transfected cells
only. For inhibition and activation assays, dithiothreitol
(DTT; Sigma, Oakville, ON, Canada), Cystamine (Sigma),
KCC-009 (provided by Dr K.M. Rich, Washington Uni-
versity, St. Louis, MO, USA), Z-DON (Zedira, Darmstadt,
Germany), TGF-b (Peprotech, Rocky Hill, NJ, USA),
LY364947 (Tocris Bioscience, Bristol, UK), or TGF-b-
neutralizing antibody (R&D Systems (Minneapolis, MN,
USA) Ab100-NA; 15 μg/ml) was added 30 minutes after
cell plating. In the case of invadopodia assays of GFP-
shRNA-expressing cells, Texas-Red-conjugated 1% gela-
tin slides were prepared as described [31], and the num-
ber of invadopodia (loss of red fluorescence) was counted
for GFP-positive cells. To quantify the areas of degrada-
tion, pictures of fluorescent matrix were analyzed by
using ImagePro software, and degradation areas asso-
ciated with positive cells were calculated in pixels, for a
minimum of 25 cells per coverslip.
Immunofluorescence and confocal microscopy
Synoviocytes cultured on coverslips for 4 to 6 hours were
prepared as described [11] and stained by using antibodies
against p-cortactin (Cell Signaling (Danvers, MA, USA)
Ab 45569; 1:75), TG2 (ThermoScientific CUB 7402; 1:50),
and stained for actin by using Texas Red- or Alexa647-
conjugated phalloidin (Invitrogen; 1:200 or 1:50). Negative
control slides were treated with isotype-matched primary
antibodies, followed by secondary antibodies. Confocal
images were acquired by using a Fluoview 1000 scanning
confocal microscope (Olympus, Richmond Hill, ON,
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Canada) in-line with an inverted microscope equipped
with a 60× oil-immersion objective. Color channels were
scanned sequentially to avoid overlapping signals.
TGase activity assay
To evaluate the activity level of TG in vivo and in vitro,
EZ-link pentylamine-biotin (PAB) (Pierce/Thermo Scien-
tific) was used as an exogenous TGase substrate. For the
live cell activity assay, 30,000 cells were allowed to adhere
to 0.2% gelatin-coated coverslips for 30 minutes and
incubated for 3 hours with 0.75 mM PAB after addition
of treatments, as specified in the figure legends. Cover-
slips were fixed with 1% PFA, permeabilized with 0.05%
saponin, and blocked with 2% BSA. Cross-linked biotin
was detected with Alexa546-conjugated streptavidin (Invi-
trogen). Mean fluorescence intensity per cell was calcu-
lated from photographs of 20 randomly selected cells for
each treatment. To assess TGase activity in articular
homogenates, tissue lysates were prepared from freshly
excised control and CIA rats (21 days after induction)
synovial membranes, homogenized by using a bead mill
(Retsch, Newtown, PA, USA) in TGase reaction buffer
(50 mM Tris, pH 7.5; 150 mM NaCl; 5 mM CaCl2; Com-
plete (Roche)). Lysates were centrifuged, and the protein
content of the supernatants was determined by using the
Bradford method (Bio-Rad Laboratories, Mississauga,
ON, Canada). Equal amounts of protein were supplemen-
ted with 1 mM DTT and inhibitor (Z-DON, 100 μM;
KCC-009, 250 μM) or vehicle. TGase enzymatic activity
was started by addition of 5 mM PAB and allowed to
proceed at 37°C for 4 or 20 hours. Reaction was stopped
by addition of SDS loading buffer and sample boiling.
Samples were separated with SDS-PAGE and transferred
onto nitrocellulose membranes. To assess TGase activity
in articular joints, rat hind knees were injected with
0.5 mM PAB in PBS, 1.2 mM CaCl2, 0.5 mM MgCl2,
with or without 10 mM Z-DON or 250 M KCC-009, and
incubated at 37°C for 4 hours. Tissues were processed as
described earlier. In both experiments, biotin-labeled
proteins were detected with streptavidin-conjugated alka-
line phosphatase.
Western blot analysis
Whole-cell extracts were prepared by lysis of overnight
serum-starved cells in RIPA buffer. ECM protein
extracts were prepared from cells grown for 72 hours in
complete medium, as described [22]. In brief, cells were
detached with 2 mM EDTA/PBS. The remaining cell-
assembled matrix was washed with 2 mM EDTA/PBS/
0.1% deoxycholate and scraped in 2× strength Laemmli
gel-loading buffer to obtain the ECM fraction. Proteins
were immunoblotted as described [29] by using anti-
TG2 (ThermoScientific TG100; 1:500), anti-LAP (R&D
Systems Ab-246-NA; 1:1,000) or anti-actin (Sigma Ab
A5060; 1:5,000) antibodies. Band intensities were ana-
lyzed by using the Quantity One software (Bio-Rad
Laboratories).
TGF-b ELISA and luciferase assay
Quantikine ELISA for Human TGF-b 1 (R&D Systems)
was used, following the manufacturer’s instructions,
with acid-activated A-FLS supernatants. For luciferase
assays, cells were transiently transfected with p3TP-Lux
[32] by using 1 mg/ml PEI (Polysciences, Warrington,
PA, USA) in DMEM-F12 supplemented with KnockOut
Serum Replacement (Invitrogen). Twenty-four hours
after transfection, cells were starved and treated over-
night, as indicated in the figure legends. Cell lysates
were assayed for luciferase activity, as described [29].
Statistical analysis
The paired or unpaired Student t test or one-way
ANOVA test was used to assess statistical significance.
A P value smaller than 0.05 was considered significant.
Results
TG2 and TGase activity are associated with degradation
of type II collagen in CIA joints
Knee joints of control and CIA rats were prepared for
immunohistochemistry (IHC) and labeled with an ε-(g-
glutamyl)-lysine bond-specific monoclonal antibody to
obtain an estimation of the cross-linking activity of
TGase or TG2-specific antibodies. As revealed by the
intensity of labeling, both TG2 and cross-linking activity
were detectable at day 18 after the induction of arthritis
and increased progressively in the synovial membrane
and adjacent cartilage of CIA rats, except at day 32, when
the intensity of TG2 labeling declined (Figure 1A and
Additional file 1, Figure S1). At days 18 to 32, TG2 and
cross-linking labeling were predominantly expressed in
the hyperplastic synovial lining and at the synovial lining/
cartilage junction, with less activity found within the
chondrocyte layer of the cartilage (Figure 1A and Addi-
tional file 1, Figure S1). To define whether TG2 is linked
to the cross-linking activity found in synovial mem-
branes, we assessed in vivo TGase activity by measuring
biotin-pentylamide (BAP) incorporation in homogenates
of normal and arthritic synovial membrane or in whole
articular joints in the presence or absence of the inhibi-
tors KCC-009, an irreversible TGase inhibitor [33], or
Z-DON, a selective TG2 inhibitor [34]. The results indi-
cated that BAP incorporation into proteins from arthritic
synovium homogenates was increased (as revealed by the
intensity of the bands) compared with normal rat syno-
vium homogenates. In addition, the bands from both
normal and arthritic homogenates incubated in the pre-
sence of the TG2-specific inhibitor Z-DON showed
reduced intensity compared with vehicle, whereas a
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stronger reduction was obtained by using the TGs inhibi-
tor KCC-009 (see Additional file 2, Figure S2A). Further-
more, direct assessment of TGase activity into articular
joints (through intraarticular (IA) BAP injection) indi-
cated that the TGase activity inhibited by Z-DON was
located mainly in the synovial lining of arthritic joints
(see Additional file 2, Figure S2B). Similar results were
obtained with the KCC-009 inhibitor (data not shown).
To evaluate the extent of cartilage damage, the articu-
lar tissues were immunostained by using an antibody
Figure 1 The formation of ε-(g-glutamyl)-lysine bonds is associated with collagen degradation in CIA. Images (40× magnification) of
representative zones of synovial membrane/cartilage from articular tissue sections of control and arthritic rats at different times (18, 28, and 32
days) after immunization with type II collagen. Tissues were immunostained with (A) ε-(g-glutamyl)-lysine bond antibody and hematoxylin or (B)
degraded collagen antibody. Associated graphs show relative labeling intensity calculated from six random fields for each tissue section in the
synovial membrane (upper graphs) or in the cartilage (lower graphs). Each column represents mean value ± SEM of total fields from two
different tissue sections per individual rat (Ctl, n = 4; CIA, n = 8). (C) Representative images (10× magnification) of immunostaining of ε-(g-
glutamyl)-lysine bonds (red), degraded collagen (blue), and double labeling (purple) in successive CIA tissue sections (*cartilage; **bone).
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that detects a newly exposed epitope within collagenase-
cleaved type II collagen [35]. Results showed that the
intensity of degraded collagen staining in both synovial
membrane and underlying cartilage increased with time
during the development of arthritis (Figure 1B). In sec-
tions stained with hematoxylin/eosin and safranin O,
evaluation of histopathologic changes, according to a
modified Mankin scoring system [27], revealed a loss of
structural integrity of the cartilage, a reduction in pro-
teoglycan content, and synovial membrane hyperplasia,
which were more pronounced as arthritis progressed
(see Additional file 3, Figure S3). The obtained histolo-
gic scores closely reflected changes observed with TG2,
TGase, and collagen-degradation assessments. In addi-
tion, double labeling of joint tissues revealed robust
TGase activity that colocalized with collagen degrada-
tion at sites of synovial membrane invasion (Figure 1C).
These results clearly suggested an association between
cartilage degradation and TGase activity in CIA joints.
Knockdown of TG2 reduces cartilage degradation in CIA
We next examined whether silencing the expression of
TG2, the main active transglutaminase in articular carti-
lage [36], affected cartilage degradation. For this, TG2-
shRNA- or control-shRNA-expressing lentivirus was
injected IA into CIA rats. Injections were performed at
day 10 to avoid interference with the initiation of the
immune response. Tissue sections from rat hind paws
were immunostained with an antibody directed against
TG2 or ε-(g-glutamyl)-lysine epitope to assess efficiency
of the treatment. Results indicated that the high levels of
TG2 labeling and TGase activity observed in arthritic
synovial membranes from control-shRNA-treated rats
were markedly reduced in TG2-shRNA-treated animals,
reaching levels comparable to control (nonarthritic)
joints (Figure 2A, B). In parallel, immunostaining by
using an antibody directed against fragments of type II
collagen showed that the extensive zones of collagen
degradation observed in the joints of CIA rats were simi-
larly reduced in tissues of CIA rats treated with TG2-
shRNA (Figure 2C). Collectively, these data suggested
that TG2 is the main enzyme involved in cross-linking
activity and cartilage degradation in CIA rats.
TG2 expression and TGase activity are increased in
arthritic FLSs
Because it is well established that FLSs play a major role
in cartilage degradation, we next assessed the levels of
TG2 expression and TGase activity in rat synovial cell
cultures. Immunoblot analysis of intracellular, secreted,
and matrix-bound TG2 revealed an absence of consistent
differences with respect to intracellular and secreted TG2
between experimental and control rats (data not shown).
In marked contrast, a reproducible increase in the
deposition of TG2 in the laid-down ECM was found in
arthritic FLS cultures compared with control FLSs
(Figure 3A). In addition, A-FLSs cultured on a gelatin
matrix displayed consistently higher TGase activity (aver-
aging 2.5-fold) than did C-FLSs (Figure 3B and Addi-
tional file 4, Figure S4A).
Knockdown of TG2 reduces the formation of invadopodia
by arthritic FLSs
Recent evidence indicated that the ECM degradation
activity of rat A-FLS in vitro and in arthritic joints is
associated with the formation of ECM-degrading cell
structures, which are reminiscent of invadopodia pro-
duced by cancer cells or podosomes in osteoclasts
[10,11]. We therefore investigated whether the modula-
tion of TG2 in A-FLSs affected their capacity to form
ECM-degrading invadopodia. Confocal microscopy ana-
lysis revealed that 81% ± 4.3% of invadopodia structures,
identified by clusters of actin and p-cortactin, two bona
fide markers of invadopodia [37], colocalized with TG2
(Figure 3C). Of significance, knockdown of TG2 caused a
drastic decrease in the percentage of cells forming inva-
dopodia, as well as in the extent of ECM degradation
induced by invadopodia (Figure 3D, E). In contrast,
knockdown of FXIIIa, a parental TG, which is also
expressed in synovial cells (Figure 3F), failed to reduce
invadopodia formation or ECM degradation (Figure 3D,
E). Immunoblotting experiments confirmed the efficiency
of TG2 and FXIIIa knockdown (Figure 3F). Furthermore,
TG2 knockdown resulted in a strong decrease in total
TGase activity, whereas knockdown of FXIIIa had a
milder effect (Figure 3G and Additional file 4, Figure
S4B), confirming that TG2 was responsible for the major-
ity of the TGase activity in A-FLSs. Together, these
results indicated that TG2 was involved in the formation
of ECM-degrading invadopodia in arthritic FLSs.
The TGase activity of TG2 is involved in invadopodia
formation in rat and human FLSs
We next examined whether modulation of the TGase
activity of TG2 affected the capacity of FLSs to form inva-
dopodia. For this, TGF-b, a potent inducer of TG2 and its
TGase activity [21,38], and DTT, a disulfide-bond reducer
that unfolds TG2, inducing its TGase activity [39], were
added to C-FLS at the onset of invadopodia assays. Results
showed that each treatment induced a strong increase in
cross-linking activity (2.2- and 2.5-fold increases, respec-
tively) as compared with untreated C-FLS, whereas the
relative levels of TG2 protein were only mildly affected
(Figure 4A and Additional file 4, Figure S4C). In contrast,
cystamine, a competitive inhibitor of TGase [40], strongly
reduced the cross-linking activity of C-FLS (Figure 4A and
Additional file 4, Figure S4C). These TGase inhibitors/
activators were also tested in invadopodia assays. TGF-b
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and DTT treatment induced 4.3- and 3.1-fold increases,
respectively, in the percentage of control synovial cells
forming invadopodia (Figure 4B). The stimulatory effect of
TGF-b was blocked by shRNA-dependent TG2 depletion
(Figure 4B). In addition, preincubation of A-FLSs with
cystamine, the TGase inhibitor KCC-009, or the TG2-spe-
cific inhibitor Z-DON, induced a significant dose-depen-
dent decrease in the formation of invadopodia without
affecting cell viability (Figure 4C and data not shown).
These results indicated that modulation of the TGase
activity of TG2 influenced invadopodia formation in FLSs.
Further to evaluate the role of the TGase activity of TG2,
C-FLSs were transfected with a TGase-defective mutant
(TG2-W214A), which is efficiently secreted (data not
shown), or wild-type TG2 (TG2 WT), and assayed for
invadopodia formation. Overexpression of TG2-W214A
Figure 2 TG2 knockdown reduces collagen degradation in CIA rats. Representative images (10× magnification) of immunostaining of (A)
TG2, (B) ε-(g-glutamyl)-lysine bonds, and (C) degraded collagen in the synovial membranes from control rats (PBS; n = 5), CIA rats injected with
control (CIA+Ctl-sh; n = 6), or TG2 (CIA+TG2-sh; n = 5) shRNA-expressing lentivirus. Associated graphs show relative labeling intensities for these
experimental groups and CIA control (n = 4) rats, calculated from three random fields for each tissue section. Values are expressed as the mean
± SEM (***P < 0.001).
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resulted in weak invadopodia formation. Furthermore, this
mutant TG2 failed to promote ECM degradation, in con-
trast to control cells harboring WT TG2 (Figure 4D, E).
These results strongly suggest that TG2 acted through
TGase activity for the regulation of invadopodia formation
in rat FLSs.
To determine whether our findings could be applied
to human arthritis, studies were performed by using
synovial cells derived from control (arthritis-free; C-
FLSs) and rheumatoid arthritis patients (RA-FLSs).
Treatment of C-FLSs with either TGF-b or DTT caused
2.7- and 6.5-fold increases, respectively, in invadopodia
formation (Figure 4F). In contrast, silencing TG2
expression by using TG2-shRNA or inhibition of TGase
activity with cystamine in synovial cells from RA
patients resulted in marked decreases in invadopodia
formation, reaching levels similar to those found in con-
trol FLS (Figure 4G). These data led us to conclude that
TG2 acted, at least in part, through its TGase activity to
regulate invadopodia formation in rat and human syno-
vial cells.
TGase-mediated induction of matrix degradation is
dependent on TGF-b production and signaling in FLSs
To gain insight into the mechanism by which TG2 influ-
ences invadopodia formation and ECM degradation, we
investigated the ability of TG2 to affect the bioavailability
of TGF-b. TG2 has been shown to enhance TGF-b pro-
duction and to contribute to TGF-b bioactivation by
favoring the binding of latent TGF-b-binding protein-1
to ECM, which is a prerequisite to TGF-b release [22,41].













































































































































Figure 3 TG2 expression and matrix degradation are increased in FLSs from CIA rats. (A) Control FLSs (C-FLSs) and arthritic FLSs (A-FLSs)
were cultured for 72 hours, and TG2 in the ECM laid down by the cells was visualized with immunoblotting. Graph shows the densitometric
analysis of TG2/actin ratio (n = 4) with representative immunoblot (insert). (B) C-FLSs and A-FLSs were cultured on gelatin, and TGase activity
was measured by using in situ 5-(biotinamido)-pentylamine incorporation assay. Graph shows mean labeling intensities of 20 cells per
experiment (n = 3). (C) Representative confocal microscopy image (60×) of the basal surface of the cell showing localization of endogenous F-
actin (red), p-cortactin (blue), and TG2 (green) and overlay of the three channels (merge) in RA-FLSs grown on gelatin for 16 hours. Arrows show
the position of the actin and p-cortactin dots that colocalize with TG2. (D through G) A-FLSs were transfected with FXIIIa-, TG2-, or their
respective control (scrambled)-shRNA-expressing lentivirus. (D) The percentage of invadopodia-forming cells was counted for 100 GFP-expressing
cells (TG2-shRNA) or 300 cells (FXIIIa-shRNA), and (E) the mean area of degradation per cell was calculated for 25 transfected cells (n = 3). (F)
Representative immunoblot of TG2 or FXIIIa and actin showing knockdown with respective shRNA. (G) In situ TGase activity was measured in a
minimum of 20 cells (n = 3). Values are expressed as the mean ± SEM (*P < 0.05; **P < 0.01; ***P < 0.001).
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increase in the production of TGF-b (Figure 5A), whereas
a 4.6-fold increase in invadopodia formation was
observed (Figure 5B) as compared with control cells
transfected with an empty vector. The invadopodia-pro-
moting effect of TG2 was completely inhibited by TGF-
b1-3 neutralizing antibodies (Figure 5B). A similar inhibi-
tion was observed by treating TG2-overexpressing cells
with the TGF-b R1 inhibitor, LY364947 (Figure 5C). In
addition, silencing TG2 expression in arthritic FLSs
inhibited TGF-b production (Figure 5D) and reduced
TGF-b activity, as measured by using the p3TP-LuX
reporter construct (Figure 5E). Taken together, these
results indicate that endogenous TGF-b was part of the
mechanism by which TG2 influenced invadopodia
formation in arthritic synoviocytes. They further suggest
that TGF-b expression and activity were regulated by
TG2 in these cells.
Discussion
An increase in the expression of TG2 or its transgluta-
minase activity is characteristic of numerous diseases
[12]. TG2 is important in the regulation of cell/ECM
interactions and is essential for many invasion-related
cellular processes, including cell adhesion, cell spread-
ing, and escape from anoikis, but the involvement of
TGase activity in ECM degradation remains unknown.
In this study, we present clear evidence that the TGase
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Figure 4 TGase activity of TG2 is involved in in vitro matrix degradation by FLSs. (A) C-FLSs were incubated with TGF-b (20 ng/ml), DTT (1
mM), or cystamine (100 μM ). After 3 hours, TG2 expression was evaluated with Western blotting (n = 2), and TGase activity was measured for
cells incubated on gelatin matrix (n = 7). (B) C-FLSs or C-FLSs transfected with TG2-shRNA-expressing lentivirus or (C) A-FLSs were cultured on a
gelatin matrix, incubated with TGF-b (20 ng/ml), DTT (1 mM), cystamine (10 or 100 μM), KCC-009 (25 or 250 μM), or Z-DON (1 or 100 μM), and
the percentage of cells forming invadopodia at 24 hours was counted for 300 cells per experiment (n = 3). (D, E) C-FLSs were transfected with
wild-type TG2 (TG2 WT), TG2-W241A, or empty vector and cultured on gelatin for 24 hours. (D) The percentage of cells forming invadopodia for
100 transfected cells (overexpressing TG2) per experiment (n = 3) and (E) the mean area of degradation per cell calculated for 25 transfected
cells (n = 3) is shown. (F) Human C-FLSs treated with TGF-b (5 and 10 ng/ml) or DTT (0.1 and 1 mM) or (G) synoviocytes from patients with
rheumatoid arthritis (RA-FLSs) transfected with GFP-tagged control- or TG2-shRNA-expressing lentivirus or treated with cystamine (10 and 100
μM) were grown on gelatin, and the percentage of GFP-expressing invadopodia-forming cells was counted at 24 hours (n = 3). Values are
expressed as the mean ± SEM (*P < 0.05; **P < 0.01; ***P < 0.001).
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degradation in CIA. We also described, for the first
time, a role for TG2 in invadopodia formation and ECM
degradation by synovial cells from CIA rats and human
arthritis patients.
The TGs family comprises at least eight members,
including the tissue/cytosolic (TG1, TG2, TG3, TG4,
TG5, TG6, and TG7) and the plasma (FXIIIa) form [42].
All of them seem to be widely distributed and to cata-
lyze the formation of g-glutamyl cross-links in a wide
range of substrates that include histones, cytoskeleton
proteins, collagens, osteopontin, osteonectin, and fibro-
nectin [42]. Among the TGs, FXIIIa and TG2 were
found to be expressed in low amounts in OA joints,
whereas their level of expression was substantially
increased (especially for TG2) in rheumatoid lesions
[43]. Also, enhanced TGase activity has been detected in
synovial fluids from RA patients [44]. Here, we showed
that the level of TGase activity in CIA joints (expressed
mostly by the hyperplastic/invading synovial membrane)
is related to the extent of cartilage degradation. We also
demonstrated that TG2 knockdown in arthritic joints
caused more than 70% decrease in both TGase activity
and cartilage degradation; such inhibition corresponds
to the efficiency of lentivirus infection in synovial cells.
Although arthritic synovial cells express both TG2 and
FXIIIa, knockdown of the individual enzymes indicated
that the majority of cross-linking activity in these cells
arises from TG2. The capacity of these cells to form the
ECM-degrading invadopodia structures was also asso-
ciated with TG2. Although one cannot rule out the par-
ticipation of other TGs, our data clearly suggested that
TG2 is the major TGase involved in cartilage degrada-
tion in CIA. In support of our interpretation, Orlandi et
al. [26] reported decreases in cartilage degradation in
TG2-knockout mice, in a surgical model of osteoarthri-
tis. Furthermore, exogenous administration of TG2 has
been shown to enhance the severity of arthritis and joint
destruction in mouse CIA [45].
FLSs are known to play a major role in the pathogen-
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Figure 5 TGase-mediated induction of matrix degradation is modulated by TGF-b in FLSs. (A-C) C-FLSs were transfected with TG2 or
empty vector. (A) Immunoblot analysis using anti-LAP antibody in cell lysates. Densitometric measurements of LAP-to-actin ratios are shown (n
= 11). (B) Cells were deposited on a gelatin matrix and incubated with control (Ctl)-IgG or anti-TGF-b antibodies. After 24 hours, the percentage
of invadopodia-forming cells was counted (n = 4). (C) Cells were deposited on a gelatin matrix and incubated for 24 hours with LY-364947 (50
nM to 500 nM), and the percentage of invadopodia-forming cells was counted (n = 4). (D, E) Arthritic FLSs were transfected with control- or
TG2-shRNA-expressing lentivirus. (D) Total TGF-b was measured with ELISA (n = 4). (E) shRNA-expressing cells were transiently transfected with
p3TP-LuX, and luciferase assays were performed (n = 4). Values are expressed as the mean ± SEM (*P < 0.05; ***P < 0.001).
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destruction of the underlying cartilage [46]. To obtain
further insight into the mechanisms by which TG2 trig-
gers cartilage degradation, we investigated the role of
TG2 in the formation of invadopodia structures, which
have been previously shown to be involved in joint
destruction [11]. We found that the levels of TG2
deposited in the ECM were markedly increased in A-
FLS cultures. By using modulators of TGase activity,
TGase and TG2-specific inhibitors, or a TGase mutant
of TG2, we showed that the degrading capacity of both
rat and human A-FLSs as well as TG2-overexpressing
normal FLS was, for the most part, related to its cross-
linking (TGase) activity. The TGase activity of TG2 has
been shown to be responsible for the increased deposi-
tion of matrix components such as fibronectin, which is
potentially implicated in pannus formation [47], as well
as the assembly of fibronectin in organized strands in
the ECM [48]. This TG2-specific fibronectin remodeling
has also been reported to increase cell adhesion to fibro-
nectin [49], an important step in invadopodia formation
by cancer cells. This suggests that matrix cross-linking
by TG2 may influence invadopodia formation by alter-
ing the composition and conformation of important
ECM constituents.
TG2 plays an important role in mesenchymal tissue
remodeling, where its function in cell adhesion, mesench-
ymal transition, and matrix stabilization not only are
important in normal wound healing but also can be
involved in disease states such as cancer, tissue fibrosis,
celiac disease, neurodegeneration, and osteoarthritis
[22,42,50-52]. The ability of TG2 to regulate most of
these various cellular and pathologic functions has been
linked to its role in TGF-b expression and bioactivation
in fibroblasts, breast and ovarian cancer cells, and renal
epithelial cells [22,50,53-55]. Through its TGase activity,
TG2 was found to regulate ECM deposition of the LTBP-
complexed latent TGF-b [41,56], an important step in the
regulation of TGFb bioavailability. TG2 also modulated
the expression and activation of TGF-b in an NF-B-
dependent manner [55,57]. We showed here that TG2
regulates TGF-b expression and TGF-b activity in syno-
vial cells. Furthermore, inhibition of TGF-bR1 activation
or TGF-b1-3 neutralization resulted in a significant loss
in the formation of TG2-dependent invadopodia-like
structures, suggesting that the modulation of endogenous
TGF-b production/bioactivation is one mechanism by
which TG2 influences invadopodia formation in A-FLS.
Conversely, TG2 was found to be necessary for TGF-b-
induced invadopodia formation, and our preliminary data
indicate that this growth factor is in part responsible for
enhanced TG2 secretion (needed for its extracellular
cross-linking activity) in arthritic synovial (data not
shown). These findings, together with the observation
that TG2 has a canonic TGF-b responsive element within
its promoter region [21,50], further suggest that
enhanced TG2 expression/activation might be a way by
which TGF-b propagates the amplification circuit in
arthritic synovial cells.
Previous findings have indicated that exogenous TGF-b
triggers invadopodia formation in breast cancer cells
through a signaling mechanism involving Src activation
[58]. Src activity has been found to be essential for the
formation of invadopodia in a variety of cancer cells [59].
We also reported that invadopodia formation in A-FLS is
related to Src activity [11]. Interestingly, inhibition of Src
activity in synovial cells completely blunted invadopodia
formation because of TG2 overexpression (see Additional
file 5, Figure S5) and as documented here for TG2, Src
activity was shown to be overexpressed in the synovial
lining of CIA joints [11]. It is therefore possible that acti-
vated Src mediates the deleterious effect of TG2 on carti-
lage integrity. Further studies will be needed to elucidate
the exact mechanism by which TG2 and Src influence
invadopodia formation and cartilage degradation by FLS.
Although significant advances have been made in
recent years in the treatment of arthritis, the commonly
used approaches are associated with untoward side
effects, and their efficacy against joint erosion remains
limited [60]. Recent studies have highlighted the thera-
peutic potential of targeting TG2 for the treatment of
various diseases, including neurodegenerative disorders,
inflammatory diseases, and fibrotic diseases [53,61-65].
Our results indicate that TG2, mostly through its TGase
activity, plays a critical role in experimental arthritis by
promoting the breakdown of cartilage components by
synovial cells. Inhibitors of the TGase activity of TG2 in
rat models have shown efficacy in reversing the inflam-
mation and fibrosis associated with chronic kidney dis-
eases and inflammatory uveitis without apparent toxicity
or side effects [66,67]. These observations suggest that
TGase inhibition may provide a promising approach for
the development of therapies aimed at stopping the pro-
cess of cartilage degradation in arthritis.
Additional material
Additional file 1: Figure S1. TG2 expression is increased in synovial
tissues in CIA. (A) Representative images (40× magnification) of synovial
membrane/cartilage from articular tissue sections of control and arthritic
rats at different times (18, 28, and 32 days) after immunization with type
II collagen. Tissues were immunostained with TG2. (B, C) Graphs show
relative labeling intensity calculated from six random fields for each
tissue section in the (B) synovial membrane or in the (C) cartilage. Each
column represents mean value ± SEM of total fields from two different
tissue sections per individual rat (Ctl, n = 4; CIA, n = 8).
Additional file 2: Figure S2. TG2 is linked to the cross-linking
activity in synovial tissues. (A) Synovial tissues from control (PBS) and
CIA rats were incubated with biotin-pentylamide (PAB) in the presence
or absence of 250 μM KCC-009 (KCC) or 100 μM Z-DON and revealed by
Western blotting. (B) PAB was injected in PBS or CIA articulations with or
without Z-DON (100 μM) and revealed by immunochemistry with
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streptavidin-peroxidase. Neg Ctl, control tissue without biotin-
pentylamide.
Additional file 3: Figure S3. Evaluation of CIA progression by using
a modified Mankin scoring system. Histopathologic classification of
the severity of arthritic lesions was evaluated by using a modified Mankin
scoring system. Graph shows mean values ± SEM for control and arthritic
rats at different times (18, 28, and 32 days) after immunization with type
II collagen (Ctl, n = 4; CIA, n = 8).
Additional file 4: Figure S4. Modulation of TGase activity is
associated with TG2 regulation. (A-C) TGase activity was measured by
using in situ 5-(biotinamido)-pentylamine incorporation assay in (A) C-
FLSs or A-FLSs cultured on gelatin matrix. (B) A-FLSs were transfected
with control- or TG2-shRNA-expressing lentivirus. (C) C-FLSs were
incubated with TGF-b (20 ng/ml), DTT (1 mM), or cystamine (100 μΜ).
Additional file 5: Figure S5. Src is implicated in TG2-mediated
invadopodia formation. C-FLSs were transfected with a TG2-expressing
or a control (empty) plasmid and cultured on gelatin in the presence or
absence of PP2. After 24 hours, the percentage of invadopodia-forming
cells was counted. Values are expressed as the mean ± SEM (*P < 0.05;
**P < 0.01; ***P < 0.001).
Abbreviations
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